Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (IMNM) is a cutting-edge biotechnology firm specializing in the development of innovative cancer immunotherapies. Grounded in leveraging the human immune system, Immunome's unique approach involves utilizing the 'most highly educated' immune systems from patients who have successfully fought off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and patient-derived, native antibodies that target those antigens.
The company employs a comprehensive suite of high-content screening technologies to identify specific and high-affinity antibodies that hold significant therapeutic potential. By harnessing these advanced techniques, Immunome aims to revolutionize cancer treatment and improve patient outcomes.
Immunome's primary pipeline includes promising preclinical and clinical assets, such as IM-1021 targeting fibroblast activation protein (FAP) and IM-4320, aimed at transforming the therapeutic landscape of oncology and infectious diseases, including COVID-19. The company is strategically positioned within the U.S. and focuses on establishing a broad spectrum of assets that can be efficiently developed through successive value inflection points.
The latest developments and achievements of Immunome reflect its commitment to innovation and excellence in the biopharmaceutical sector. The latest news showcases significant milestones, partnerships, and advancements in their research and development efforts, further solidifying their reputation as leaders in the field of antibody therapeutics.
Immunome (Nasdaq: IMNM) has submitted a preprint manuscript detailing the preclinical efficacy of its SARS-CoV-2 antibody cocktail, IMM-BCP-01. This cocktail includes three monoclonal antibodies targeting regions of the spike protein, showing significant viral load reduction in infected hamsters. In tests, IMM-BCP-01 demonstrated a potent reduction of live viral titers by approximately 3.2 - 4 logs. This research indicates broad protective capabilities against multiple variants, supporting the potential for non-intravenous delivery in humans.
Immunome, Inc. (Nasdaq: IMNM) presented findings on its anti-interleukin-38 monoclonal antibody program at the 2021 AACR-NCI-EORTC International Conference. The presentation revealed that the antibody effectively binds to IL-38, preventing its interaction with receptors and enhancing myeloid cell activity in vitro. In murine tumor models, the antibody significantly inhibited tumor growth. This data suggests that blocking IL-38 could potentially reverse immune suppression in tumors, providing a promising avenue for cancer treatment.
Immunome, Inc. (NASDAQ: IMNM) announced an oral poster presentation of its anti IL-38 antibody program at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 7-10, 2021. The presentation, titled “IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody,” will cover the antibody's effectiveness in inducing robust anti-tumor responses in vivo. This marks a significant milestone for Immunome as it advances its therapeutic programs targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company focused on antibody therapeutics, announced that President and CEO Purnanand Sarma, Ph.D., will present at the Cantor Global Healthcare Conference on September 29, 2021, at 8:40 a.m. ET. Interested parties can access the live audio webcast through the company's Investor Relations page. Immunome leverages its human memory B cell platform to develop first-in-class therapeutics targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM) announced that its President and CEO,
Immunome, Inc. (Nasdaq: IMNM) announced that its antibody cocktail, IMM-BCP-01, showed strong neutralizing activity against the Lambda and Delta variants of SARS-CoV-2 in pre-clinical studies. The cocktail targets non-overlapping regions of the spike protein, proving effective against multiple strains. Funded by the U.S. Department of Defense, this promising therapeutic aims to combat COVID-19 variants. CEO Purnanand Sarma emphasized the ongoing support from pre-clinical data, reinforcing the importance of IMM-BCP-01 in fighting emerging variants.
Immunome, Inc. (Nasdaq: IMNM) reported robust progress in Q2 2021, particularly in developing IMM-BCP-01, an antibody cocktail targeting SARS-CoV-2. The company secured increased funding from the Department of Defense and demonstrated strong neutralization activity against the Delta variant in preclinical tests. An IND filing for IMM-BCP-01 is planned for Q3 2021, with additional plans for an IL-38 immuno-oncology IND filing in Q4 2021. Financially, R&D expenses were $3.2 million, and the net loss totaled $5.2 million, with cash reserves at $59.8 million.
Immunome (Nasdaq: IMNM) announced promising results for its three-antibody cocktail, IMM-BCP-01, which showed potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical tests. The company received a $17.6 million award from the U.S. Department of Defense to support its COVID program. With concerns over potential COVID-19 resurging due to new variants, Immunome plans to expedite the development of IMM-BCP-01 and submit an IND application to the FDA this quarter, potentially positioning the drug as a long-term solution to COVID-19.
Immunome, a biopharmaceutical company focused on first-in-class antibody therapeutics, announced that its President and CEO, Purnanand Sarma, Ph.D., will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, at 10:30 a.m. ET. The presentation can be accessed via a live audio webcast on the company’s website, with a replay available for 30 days. Immunome leverages its human memory B cell discovery engine to develop therapies for oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM) has appointed Andrew D. Badley, M.D., to its COVID-19 Advisory Board. Dr. Badley, Chair of the Mayo COVID-19 Research Taskforce, is recognized for his expertise in infectious diseases and will provide critical insights as Immunome develops antibody therapeutics for COVID-19 and other outbreaks. His extensive background includes significant roles at the Mayo Clinic and a focus on virus-host interactions, aiming to enhance therapeutic approaches in infectious diseases.
FAQ
What is the current stock price of Immunome (IMNM)?
What is the market cap of Immunome (IMNM)?
What does Immunome, Inc. specialize in?
What is the core technology platform of Immunome?
What are the primary focus areas for Immunome?
Can you name some of Immunome's key pipeline assets?
Where is Immunome, Inc. based?
What is the goal of Immunome's development strategy?
How does Immunome identify high-affinity antibodies?
What distinguishes Immunome's approach to immunotherapy?
How does Immunome plan to impact cancer treatment?
What recent achievements has Immunome made?
